Diabetes, insulin resistance, and dementia among HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 1, 2005, Pages 31-36

  Valcour, Victor G ^a,c   Shikuma, Cecilia M ^a   Shiramizu, Bruce T ^a   Williams, Andrew E ^a   Watters, Michael R ^a   Poff, Pamela W ^a   Grove, John S ^a   Selnes, Ola A ^b   Sacktor, Ned C ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Leahi Hospital   (United States)

Author keywords

Dementia; Diabetes mellitus; HIV 1; Insulin resistance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONSENSUS DEVELOPMENT; DEMENTIA; DEMOGRAPHY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATION; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLIC PARAMETERS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; HAWAII; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 11844304903     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200501010-00006     Document Type: Article

References (33)

1. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423-1427.
2. Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
3. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;94:515-519.
4. Walli R, Goebel FD, Demant T. Impaired glucose tolerance and protease inhibitors. Ann Intern Med. 1998;129:837-838.
5. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
6. Dever LL, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother. 2000;34:580-584.
7. Calza L, Manfredi R, Farneti B, et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003;22:54-59.
8. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs. 2003;63:2555-2574.
9. DeCarli C. The role of cerebrovascular disease in dementia. Neurology. 2003;9:123-136.
10. Barbaro G. HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res. 2003;60:87-95.
11. Holmberg SMA, Tong T, Ward D, et al. 698-T: protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA. February 24-28, 2002.
12. Mary-Krause L, Cotte L, Partisani M, et al. T-657: impact of treatment with protease inhibitor on myocardial infarction occurrence in HIV-infected men. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago, IL. February 4-8, 2001.
13. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
14. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV+ individuals. The Hawaii Aging with HIV Cohort. Neurology. 2004;63:822-827.
15. Marder K, Liu X, Stern Y, et al. Neurologic signs and symptoms in a cohort of homosexual men followed for 4.5 years. Neurology. 1995;45:261-267.
16. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785.
17. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
19. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181(Suppl 3):S462-S472.
20. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377-1382.
21. Chow DC, Souza SA, Chen R, et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4:411-416.
22. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
23. Leibson CL, Rocca WA, Hanson VA, et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci. 1997;826:422-427.
24. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997;315:1045-1049.
25. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169-178.
26. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care. 1998;21:398-402.
27. Gasparini L, Netzer WJ, Greengard P, et al. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci. 2002;23:288-293.
28. Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983;7:590-598.
29. Foster NL, Chase TN, Fedio P, et al. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology. 1983;33:961-965.
30. Haxby JV, Grady CL, Friedland RP, et al. Neocortical metabolic abnormalities precede nonmemory cognitive impairments in early dementia of the Alzheimer type: longitudinal confirmation. J Neural Transm Suppl. 1987;24:49-53.
31. Sims NR, Finegan JM, Blass JP, et al. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res. 1987;436:30-38.
32. Watson GS, Peskind ER, Asthana S, et al. Insulin increases CSF Abeta42 levels in normal older adults. Neurology. 2003;60:1899-1903.
33. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003;28:809-822.